Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer

PaperCitations, authors & open-access status

Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 79 citations, 1997 year and bronze oa status.

79
Citations
1997
Year
bronze
OA Status

Related on ScholarIQ

Monica Martoni
Author
Annals of Oncology
Journal
Cancer Treatment and Pharmacology
Topic
Cancer Treatment and Pharmacology
Topic
Chemotherapy-induced cardiotoxicity and mitigation
Topic
Breast Cancer Treatment Studies
Topic
470M+ articles · free account